Pontine Glioma Drugs Global Market Report 2024

The pontine glioma drugs market size has grown rapidly in recent years. It will grow from $0.88 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to research efforts and clinical trials, growing awareness and acceptance, and advancements in medical imaging.

The pontine glioma drugs market size is expected to see rapid growth in the next few years. It will grow to $1.5 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The rise anticipated during the forecast period is due to progress in precision medicine, international cooperation and financial support, immunotherapy breakthroughs, and targeted treatment methods. Key trends expected include advancements in immunotherapy, utilization of nanotechnology, developments in gene therapy, combined treatment approaches, and shifts in regulatory policies.

The surge in demand for personalized medicine is anticipated to drive the expansion of the pontine glioma drugs market in the future. Personalized medicine represents a pioneering approach that utilizes information regarding an individual's genetic makeup, environmental influences, and lifestyle choices to inform medical treatment decisions. The increasing interest in personalized medicine stems from its potential to offer more tailored and efficacious therapies, advancements in genomic research, the growing complexity of diseases, and regulatory backing. In the treatment of pontine gliomas, personalized medicine plays a significant role by customizing treatments based on the tumor's specific genetic characteristics and the unique attributes of each patient. For example, in February 2024, the Food and Drug Administration (FDA) greenlit 16 groundbreaking personalized therapies for rare disease patients in 2023, marking a notable increase from six approvals in 2022, as reported by the Personalized Medicine Coalition, a US-based non-profit organization. Hence, the ascent of personalized medicine is propelling the expansion of the pontine glioma drugs market.

Prominent companies in the pontine glioma drugs sector are directing their efforts towards the development of inventive products, such as small-molecule chemotherapeutics, to optimize their market revenues. Small-molecule chemotherapeutics constitute medications comprising compounds with relatively low molecular weights, facilitating their efficient penetration through the blood-brain barrier to target the site of pontine glioma tumors. For instance, in December 2022, Kintara Therapeutics, a US-based clinical-stage pharmaceutical company, secured an orphan drug designation from the U.S. Food and Drug Administration (FDA) for VAL-083. This medication aims to address diffuse intrinsic pontine glioma (DIPG). VAL-083 stands out as a pioneering small-molecule chemotherapeutic with a distinctive mechanism of action, demonstrating clinical efficacy against various cancers, encompassing central nervous system malignancies, ovarian tumors, and other solid cancers. This designation underscores the promising potential of VAL-083 as a therapeutic option for combating this formidable brain tumor, emphasizing the commitment to addressing the unmet medical necessities associated with DIPG treatment.

In January 2021, Chimerix Inc., a biopharmaceutical company headquartered in the United States, acquired Oncoceutics Inc. for an undisclosed sum. This acquisition is geared towards bolstering Chimerix's pipeline through the integration of a late-stage oncology program. Oncoceutics Inc. is a biotechnology firm based in the U.S. that focuses on the development of medications for addressing H3 K27M-mutant gliomas, which encompass diffuse intrinsic pontine glioma (DIPG).

Major companies operating in the pontine glioma drugs market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries, Daiichi Sankyo Company Limited, The Menarini Group, Y-mAbs Therapeutics, Agios Pharmaceuticals, Kazia Therapeutic, DNAtrix Inc., Aminex Therapeutics Inc., Accendatech Co Ltd, Arog Pharmaceuticals, Kintara Therapeutics Inc., Medicenna Therapeutics, Alaunos Therapeutics, Biodexa Pharmaceuticals PLC.

North America was the largest region in the pontine glioma drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pontine glioma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pontine glioma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pontine glioma drugs refer to pharmaceuticals formulated specifically to address pontine gliomas, which are malignant brain tumors located in the pons, a critical area of the brainstem. These medications are developed with the primary objectives of reducing tumor size or growth rate, mitigating associated symptoms, and enhancing the overall well-being and comfort of patients.

The primary categories of pontine glioma drugs include diffuse brain stem glioma, focal brain stem glioma, and recurrent brain stem glioma. Diffuse brain stem glioma denotes a specific form of brain tumor emerging within the brain stem, the area governing crucial bodily functions such as respiration and heart rhythm. These medications are distributed through diverse channels, encompassing hospital pharmacies and retail outlets, and are applied across various sectors, including cancer research institutes, diagnostic laboratories, and medical facilities.

The pontine glioma drugs market research report is one of a series of new reports that provides pontine glioma drugs market statistics, including pontine glioma drugs industry global market size, regional shares, competitors with a pontine glioma drugs market share, detailed pontine glioma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pontine glioma drugs industry. This pontine glioma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pontine glioma drugs market consists of sales of belzutifan, carboplatin, temozolomide, bevacizumab, and carmustine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.